AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the target of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 6,805,914 shares, a drop of 15.4% from the November 15th total of 8,047,193 shares. Based on an average daily volume of 1,479,580 shares, the short-interest ratio is currently 4.6 days. Currently, 7.0% of the company’s shares are sold short.
Several brokerages recently commented on AVEO. Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. B. Riley assumed coverage on AVEO Pharmaceuticals in a report on Monday, November 13th. They issued a “buy” rating and a $5.00 price objective for the company. started coverage on AVEO Pharmaceuticals in a report on Wednesday, November 15th. They set a “buy” rating and a $5.00 price target for the company. BidaskClub downgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday. Finally, Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $4.05.
Several institutional investors and hedge funds have recently bought and sold shares of AVEO. RA Capital Management LLC acquired a new stake in shares of AVEO Pharmaceuticals in the 2nd quarter worth about $18,727,000. Vanguard Group Inc. increased its stake in AVEO Pharmaceuticals by 48.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the last quarter. EAM Investors LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter valued at about $1,979,000. Essex Investment Management Co. LLC purchased a new stake in AVEO Pharmaceuticals in the 3rd quarter valued at about $550,000. Finally, OxFORD Asset Management LLP purchased a new stake in AVEO Pharmaceuticals in the 3rd quarter valued at about $228,000. Institutional investors own 50.91% of the company’s stock.
Shares of AVEO Pharmaceuticals (AVEO) traded down $0.03 on Thursday, reaching $2.77. 944,342 shares of the company’s stock were exchanged, compared to its average volume of 1,400,000. AVEO Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $4.24. The company has a market capitalization of $327.71, a PE ratio of -3.90 and a beta of 1.14. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32.
TRADEMARK VIOLATION WARNING: “AVEO Pharmaceuticals, Inc. (AVEO) Sees Significant Drop in Short Interest” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/aveo-pharmaceuticals-inc-aveo-short-interest-down-15-4-in-november.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.